Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors

dc.contributor.authorAzim, H. A., Jr.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorPeccatori, F. A.en
dc.date.accessioned2015-11-24T19:04:57Z
dc.date.available2015-11-24T19:04:57Z
dc.identifier.issn1532-1967-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20120
dc.rightsDefault Licence-
dc.subjectAntineoplastic Agents/administration & dosage/*therapeutic useen
dc.subjectDose-Response Relationship, Drugen
dc.subjectFemaleen
dc.subjectHematologic Neoplasms/*drug therapyen
dc.subjectHumansen
dc.subjectImmunosuppressive Agents/administration & dosage/*therapeutic useen
dc.subjectImmunotherapy/*methodsen
dc.subjectPregnancyen
dc.subjectPregnancy Complications, Neoplastic/*drug therapyen
dc.subjectPregnancy Outcomeen
dc.subjectTreatment Outcomeen
dc.titleTreatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumorsen
heal.abstractManaging pregnant patients with hematological tumors pose even more conflicts compared to solid tumors. Unlike the majority of solid tumors, hematological malignancies are potentially curable; hence it is important to deliver the best treatment options available, which sometimes could be too aggressive to deliver during pregnancy. In part II, we report the results of women with hematological malignancies treated with systemic therapies during the course of pregnancy. Lymphoma, acute leukemia and chronic myeloid leukemia were the most commonly treated. We discuss the safety of the different regimens reported and propose alternatives to standardized approaches in case they pose significant risk to the pregnancy and/or the fetus.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1016/j.ctrv.2009.11.004-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20018452-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0305737209001789/1-s2.0-S0305737209001789-main.pdf?_tid=dab99f7a1db97bd2326d3cc48266f21e&acdnat=1333609806_0eb622a73d26a3bed31c148c6e949e92-
heal.journalNameCancer Treat Reven
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2010-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: